Matthew T. Wiley - 22 Jul 2024 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Reporting relationship: Former Chief Commercial Officer
Issuer ticker: BTAI
Reported as of: 22 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2025, 18:06:16 UTC
Prior SEC filing: 17 Sep 2024
Next SEC filing: 17 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Richard Steinhart, as Attorney-in-Fact for Matthew Wiley

Key filing fact

Matthew T. Wiley filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 01 Apr 2025.

Key facts

This page summarizes Matthew T. Wiley's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Apr 2025, 18:06.

Change

Previous filing in this sequence was filed on 17 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BTAI transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,875
Change %
Price: $0.000000
Shares after: 1,875
Date: 22 Jul 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,875
Exercise price: $1.20
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Matthew T. Wiley is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock.

Footnote F2

The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Due to the Reporting Person's termination of employment, the unvested Stock Option was forfeited.

SEC remarks

Former Chief Commercial Officer